HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.

Abstract
Parainfluenza virus (PIV) can cause significant morbidity after allogeneic stem cell transplantation (SCT). We report the first use of inhaled DAS181 for PIV in an allogeneic SCT recipient. Symptoms, oxygenation, and pulmonary function tests improved. Nasopharyngeal samples showed a reduction in viral load. DAS181 should be systematically evaluated for severe PIV infection.
AuthorsYi-Bin Chen, Jessica P Driscoll, Steven L McAfee, Thomas R Spitzer, Eric S Rosenberg, Rebecca Sanders, Ronald B Moss, Fang Fang, Francisco M Marty
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 53 Issue 7 Pg. e77-80 (Oct 2011) ISSN: 1537-6591 [Electronic] United States
PMID21880586 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • Recombinant Fusion Proteins
  • oplunofusp
  • Oxygen
Topics
  • Administration, Inhalation
  • Antiviral Agents (administration & dosage)
  • Female
  • Humans
  • Immunocompromised Host
  • Middle Aged
  • Nasopharynx (virology)
  • Oxygen (blood)
  • Parainfluenza Virus 3, Human (isolation & purification)
  • Recombinant Fusion Proteins (administration & dosage)
  • Respiratory Function Tests
  • Respirovirus Infections (diagnosis, drug therapy, pathology)
  • Stem Cell Transplantation (adverse effects)
  • Transplantation, Homologous (adverse effects)
  • Treatment Outcome
  • Viral Load

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: